This is an aggregated industry headline. Read the full story at FiercePharma →
Roche tops oncology reputation rankings as AstraZeneca climbs back to 2nd place
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView's corporate reputation ranking on the back of strength in breast and lung cancer. Roche, a familiar sight at the top of PatientView's cancer rankings, claimed first place ahead of AstraZeneca and Novartis.
By FiercePharma
· Jul 2, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on…
The WeekBriefing
Tzield gains accelerated approval to delay insulin decline in children 8–17 with recently diagnosed Stage 3 ty…
The WeekPharmaceutical Technology ↗
Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Phar…